表紙
市場調査レポート

持続血糖測定システムの世界市場 - 2014〜2021年の市場機会および市場予測

World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 - 2021

発行 Allied Market Research 商品コード 335355
出版日 ページ情報 英文 118 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
持続血糖測定システムの世界市場 - 2014〜2021年の市場機会および市場予測 World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 - 2021
出版日: 2015年06月01日 ページ情報: 英文 118 Pages
概要

持続血糖測定システム (CGMS) は糖尿病管理分野での最新技術のひとつであり、今後スマートフォンやウェアラブルデバイスと連動したCGMSなどハイテクCGMSや非侵襲性CGMS、また究極的にはスマート糖尿病管理ソリューションである、人工バイオニック膵臓の登場など、広く市場に導入されるものと予測されます。このような背景の下でCGMS世界市場は2014年から2021年の期間にわたって31.4%のCAGR (年平均成長率) で急速な拡大を続け、2021年には市場規模が29億米ドルに達する見込みです

当レポートはCGMSの世界市場を精査しており、市場成長促進要因、阻害要因、新技術、市場機会、重要な戦略等を詳細に検証し、現在の市場シナリオ分析と2021年までの市場予測を行っています。この市場はCGMSの構成品別、エンドユーザ分野別、年齢層別、また地域市場別に分類することができ、当レポートではそれぞれの分類に基づいてきめ細かな市場分析と将来予測を示しています。さらにこの市場における主要企業について、業績、戦略、また最近の事業展開やSWOT分析を含め、詳細な企業プロファイルを提供しています。

第1章 序論

  • 当レポートについて
  • 主要な成果
  • 主な市場分野
  • 調査手法

第2章 エグゼクティブ・サマリー

第3章 市場概要

  • 市場の定義
  • 血糖測定システムの必要性
    • 糖尿病が世界的に流行
      • 1型糖尿病
      • 2型糖尿病
      • 前糖尿病状態と妊娠糖尿病 (GDM)
      • 二次性糖尿病
    • 糖尿病に対する世界の医療費支出
  • CGMSの新技術
    • スマートフォン接続型CGMS
    • ウェアラブルデバイスおよびスマートフォン接続型CGMS
    • 非侵襲性CGMS
    • 研究開発途上の侵襲性CGMS
    • スマート糖尿病管理ソリューション Bionic Pancreas (バイオニック人工膵臓)
  • CGMS - 重症エンドユーザ分野
    • 集中治療室 (ICU) におけるCGMSの決定的な必要性
      • ICUでありがちなストレス高血糖症
      • ICUにおける標準に合致しない誤った血糖コントロール
  • ICUにおけるCGMSの利点とCGMS導入を促す要因
    • CGMSはICUにおける厳密な血糖コントロールを支援
    • CGMSの使用に伴うコスト的利点
    • POC血糖測定器はICUにおいてはCGMSよりも効率性が低い
    • ICUの職員にはCGMSが最も好まれる
  • 重要な調査結果
    • 市場を左右する最重要要因
    • 最重要投資先分野
    • 勝ち抜くための最重要戦略
  • バリューチェーン分析
  • 市場シェア分析 - 2014年
  • 政府規制
  • 保険払い戻しシナリオ
  • 市場成長促進要因
    • 糖尿病の世界的な増加
    • POC血糖測定器よりも本来的に利点が多いことから市場成長が進む
    • 新興諸国や低開発国における認知度の高まり
    • 新たなエンドユーザ分野に向けたOTC/POC CGMSの開発重点化 - 将来の市場成長を促進
    • 米食品医薬品局 (FDA) によるBionic Pancreasの承認は将来の市場成長を促進
  • 市場成長阻害要因
    • 厳しい法規制要件
    • 不十分な保険払い戻し制度がCGMS導入の障害となる
    • 精度とコストとがCGMSの継続使用に対する障害となる
  • 市場機会
    • ICUにおけるCGMSの高い導入率
    • OTC/POC CGMS - 製品の用途/使用範囲の拡大
    • 未診断の患者数
  • 国際企業が新興国市場への参入を果たすための戦略
    • アジア太平洋市場やLAMEA (ラテンアメリカ・中東・アフリカ) 市場への迅速な参入を果たすためのCE承認の取得
    • 地域的な販売網を強化するため流通についての企業提携を構築
    • エンドユーザに対する認知度を上げること、また競争力のある製品価格を打ち出すこと

第4章 構成品別に見た持続血糖測定システム世界市場

  • 単体型および統合型CGMシステム
    • 市場規模および将来予測
  • センサー
    • 主要市場動向
      • 非侵襲型血糖センサー
      • 皮下センサー (低侵襲性センサー)
      • 従来型技術 - Holterタイプ遡及的データ集計解析センサー
      • 新技術 - リアルタイムセンサー
    • 主な市場成長促進要因および市場機会
    • 市場規模および将来予測
  • トランスミッターおよびレシーバー
    • 主要市場動向
    • 主な市場成長促進要因および市場機会
    • 市場規模および将来予測
  • 統合化インシュリンポンプ
    • 概要
    • 主要市場動向
    • 主な市場成長促進要因および市場機会
    • 市場規模および将来予測

第5章 エンドユーザ分野別に見た持続血糖測定システム世界市場

  • 市場規模および将来予測
  • 診断センター/医院
    • 市場規模および将来予測
  • ICU
    • 市場規模および将来予測
  • ホーム・ヘルスケア
    • 市場規模および将来予測

第6章 年齢層別に見た持続血糖測定システム世界市場

  • 未成年者
  • X世代
  • 老人医療 / 未診断患者

第7章 地域市場別に見た持続血糖測定システム世界市場

  • 北米
    • 市場規模および将来予測
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 主要市場動向
    • 主な市場成長促進要因および市場機会
    • フランス
    • ドイツ
    • 英国
    • その他の欧州諸国
  • アジア太平洋地域
    • 市場規模および将来予測
    • インド
    • オーストラリア
    • 中国
    • その他のアジア太平洋諸国
  • ラテンアメリカ、中東、およびアフリカ (LAMEA) 地域
    • 概要
    • 市場規模および将来予測
    • 湾岸協力会議 (GCC)

第8章 企業プロファイル

  • Medtronic Plc.
    • 会社概要
    • ビジネス業績
    • 戦略的動きと事業展開
    • SWOT分析
  • Dexcom Inc.
  • Abbott Diabetic Care (Abbott Laboratories)
  • Animas Corporation
  • Echo Therapeutics
  • Insulet Corporation
  • Glysens Inc.
  • Senseonics, Inc.
目次
Product Code: LI 15692

Title: World Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & Receivers, Integrated insulin pumps), Customer Segments (Diagnostics, ICUs, Home Healthcare) and End-user Demographics (Juveniles, Gen X, Geriatrics) - Global Opportunity Analysis and Industry Forecast, 2014 - 2021.

Continuous Glucose Monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM systems are a type of glucose monitoring devices that function by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in the interstitial fluid or in the blood and results are transmitted via a transmitter to a receiver/monitor that displays the results. CGM systems have emerged as an integral part of diabetes management owing to its several advantages over other glucose monitoring devices. Unlike conventional glucose monitors, these systems enable periodic monitoring of glucose levels, which is crucial to avoid any diabetic complications. In addition, CGMS technology has laid a roadmap to the most awaited, high-tech, closed-loop ‘artificial/bionic pancreas'. Therefore, developing novel and technologically advanced CGMS is the prime focus of several glucose monitoring device manufacturing companies. CGMS offer a wide range of applications across all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs and home healthcare) and geographies. Thus, CGMS market shows lucrative opportunity for both CGMS manufacturers and insulin pump manufacturers.

The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and ‘smart' diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.

The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics.

Detailed geographical analysis and segmentation is provided at country-level per-region-North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.

KEY BENEFITS

  • In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the CGMS market
  • Comprehensive analysis of factors that drive and restrict the growth of the CGMS market is provided
  • The report covers detailed quantitative analysis of the current market and estimations through 2014-2021, which would enable the stakeholders to capitalize on prevailing market opportunities
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
  • An in-depth analysis of current research and clinical developments within CGMS market is provided with key market dynamic factors that help in understanding the behavior of market
  • Key market players within the CGMS market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of the global CGMS market

KEY MARKET SEGMENTS

The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level).

Global CGMS Market - by Components

  • Sensors
  • Transmitters & Receivers
  • Integrated insulin pumps

Global CGMS Market - by Customer Segments

  • Diagnostics/Clinic
  • ICUs
  • Home Healthcare

Global CGMS Market - by End-user Demographics

  • Juveniles
  • Gen X
  • Geriatrics/undiagnosed

Global CGMS Market - by Geography

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Others
  • Asia-Pacific
    • China
    • India
    • Australia
    • Others
  • LAMEA
  • Gulf Cooperation Council (GCC)
  • Others

Table of Contents

Chapter 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segment
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY

Chapter 3: MARKET OVERVIEW

  • 3.1. Market definition
  • 3.2. Need for glucose monitoring systems
    • 3.2.1. Diabetes a pandemic
      • 3.2.1.1. Type 1 diabetes
      • 3.2.1.2. Type-2 diabetes
      • 3.2.1.3. Pre-diabetes and Gestational Diabetes Mellitus (GDM)
      • 3.2.1.4. Gestational Diabetes Mellitus (GDM)
      • 3.2.1.5. Secondary diabetes
    • 3.2.2. Global healthcare expenditure on diabetes
  • 3.3. Emerging technologies in CGMS
    • 3.3.1. Smartphone-connected CGMS
    • 3.3.2. Wearable and smartphone-connected CGMS
    • 3.3.3. Non-invasive CGMS
    • 3.3.4. Invasive CGMS in the R&D pipeline
    • 3.3.5. 'Smart diabetes management solution Bionic Pancreas
  • 3.4. CGMS - Prime end user segments
    • 3.4.1. CGMS crucial need in Intensive Care Units (ICUs)
      • 3.4.1.1. Stress Hyperglycemia common occurrence in ICUs
    • 3.4.1.2. Non-standardization and erroneous glycemic control across ICUs
    • 3.4.2. Benefits and factors driving adoption of CGMS in ICUs
      • 3.4.2.1. CGMS aid in Tight Glycemic Control in ICUs
      • 3.4.2.2. Cost benefits from usage of CGMS
      • 3.4.2.3. POC Glucometers less effective in ICUs - as compared to CGMS
      • 3.4.2.4. CGMS most preferred by ICU staff
  • 3.5. Key findings
    • 3.5.1. Top impacting factors
    • 3.5.2. Top investment pockets
      • 3.5.2.1. CGMS market By End User Segments
      • 3.5.2.2. CGMS market by geography
    • 3.5.3. Top winning strategies
  • 3.6. Value chain analysis
  • 3.7. Market share analysis, 2014
  • 3.8. Government regulations
  • 3.9. Reimbursement scenario
  • 3.10. Drivers
    • 3.10.1. Rise in incidence of diabetes globally
    • 3.10.2. Inherent benefits of CGMS over POC glucometers drive market growth
    • 3.10.3. Increase in awareness in developing and underdeveloped economies
    • 3.10.4. Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
    • 3.10.5. FDA, U.S. approval of Bionic Pancreas future growth driver
  • 3.11. Restraints
    • 3.11.1. Stringent regulatory requirements
    • 3.11.2. Inadequate reimbursements a barrier in CGMS adoption
    • 3.11.3. Accuracy and cost a hindrance in continuing use of CGMS
  • 3.12. Opportunities
    • 3.12.1. Higher adoption rate of CGMS in ICUs
    • 3.12.2. OTC/POC CGMS - expanded product applications/usage
    • 3.12.3. Undiagnosed patient population
  • 3.13. Winning strategies for MNCs for entering emerging markets
    • 3.13.1. Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets
    • 3.13.2. Forming distribution alliances to enhance geographical reach
    • 3.13.3. Raising end-user awareness and competitive product pricing

Chapter 4: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS

  • 4.1. Stand-alone and Integrated CGM systems
    • 4.1.1. Market size and forecast
  • 4.2. Sensors
    • 4.2.1. Key market trends
      • 4.2.1.1. Non-invasive glucose sensors
      • 4.2.1.2. Subcutaneous sensors (Minimally Invasive Sensors)
      • 4.2.1.3. Conventional technology holter-yype retrospective sensors
      • 4.2.1.4. Advanced technology Real-Time sensors
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Transmitters & Receivers
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. Integrated Insulin pumps
    • 4.4.1. Overview
    • 4.4.2. Key market trends
    • 4.4.3. Key growth factors and opportunities
    • 4.4.4. Market size and forecast

Chapter 5: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT

  • 5.1. Market size and forecast
  • 5.2. Diagnostic centers/clinics
    • 5.2.1. Market size and forecast
  • 5.3. ICUs
    • 5.3.1. Market size and forecast
  • 5.4. Home healthcare
    • 5.4.1. Market size and forecast

Chapter 6: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY AGE DEMOGRAPHICS

  • 6.1. Juveniles
  • 6.2. Gen X
  • 6.3. Geriatrics / undiagnosed

Chapter 7: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY

  • 7.1. North America
    • 7.1.1. Market size and forecast
    • 7.1.2. U.S.
    • 7.1.3. Canada
    • 7.1.4. Mexico
  • 7.2. Europe
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.4. France
      • 7.2.4.1. Key market trends
      • 7.2.4.2. Key growth factors and opportunities
    • 7.2.5. Germany
      • 7.2.5.1. Key market trends
      • 7.2.5.2. Key growth factors and opportunities
    • 7.2.6. U.K.
      • 7.2.6.1. Key market trends
      • 7.2.6.2. Key growth factors and opportunities
    • 7.2.7. Other European countries
  • 7.3. Asia-Pacific
    • 7.3.1. Market size and forecast
    • 7.3.2. India
      • 7.3.2.1. Key market trends
    • 7.3.3. Australia
      • 7.3.3.1. Key market trends
    • 7.3.4. China
      • 7.3.4.1. Key market trends
    • 7.3.5. Other APAC countries
  • 7.4. LAMEA
    • 7.4.1. Overview
    • 7.4.2. Market size and forecast
    • 7.4.3. Gulf Cooperation Council (GCC)
      • 7.4.3.1. Key market trends

Chapter 8: COMPANY PROFILES

  • 8.1. Medtronic Plc.
    • 8.1.1. Company overview
    • 8.1.2. Business performance
    • 8.1.3. Strategic moves and developments
      • 8.1.3.1. Principal strategies: product launch
      • 8.1.3.2. Secondary strategies: approval
      • 8.1.3.3. Other strategies: strategic alliance and collaboration
    • 8.1.4. SWOT analysis of Medtronic Plc
  • 8.2. Dexcom Inc.
    • 8.2.1. Company overview
    • 8.2.2. Business performance
    • 8.2.3. Strategic moves and developments
      • 8.2.3.1. Principal strategies: agreement/partnership
      • 8.2.3.2. Secondary strategies: approval
      • 8.2.3.3. Other strategies: acquisition
    • 8.2.4. SWOT analysis of Dexcom
  • 8.3. Abbott Diabetic Care (Abbott Laboratories)
    • 8.3.1. Company overview
    • 8.3.2. Business performance
    • 8.3.3. Strategic moves and developments
    • 8.3.4. SWOT analysis of Abbott diabetic care
  • 8.4. Animas Corporation
    • 8.4.1. Company overview
    • 8.4.2. Strategic moves and developments
    • 8.4.3. SWOT analysis of Animas Corporation
  • 8.5. Echo Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Strategic moves and development
    • 8.5.3. SWOT Analysis of Echo Therapeutics
  • 8.6. Insulet Corporation
    • 8.6.1. Company overview
    • 8.6.2. Strategic moves and developments
    • 8.6.3. SWOT analysis of INSULET Corporation
  • 8.7. Glysens Inc.
    • 8.7.1. Company overview
    • 8.7.2. Strategic moves and developments
    • 8.7.3. SWOT Analysis of Glysens Inc.
  • 8.8. Senseonics, Inc.
    • 8.8.1. Company overview
    • 8.8.2. Strategic moves and development
    • 8.8.3. SWOT analysis of Senseonics, Inc.

List of Tables

  • TABLE 1: FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
  • TABLE 2: FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
  • TABLE 3: GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 4: GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014 2021 ($MILLION)
  • TABLE 5: GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 6: GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014 2021 ($MILLION)
  • TABLE 7: GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
  • TABLE 8: GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 9: GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 10: GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 11: TYPE-1 DIABETES (0-14 YEARS), 2013
  • TABLE 12: FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
  • TABLE 13: GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 14: NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 15: NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 16: PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
  • TABLE 18: EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 19: TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
  • TABLE 20: PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
  • TABLE 21: APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 22: APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 23: MEDICAL DEVICES USED IN AUSTRALIA
  • TABLE 24: LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 25: LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 26: MEDTRONIC BUSINESS SNAPSHOT
  • TABLE 27: MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
  • TABLE 28: DEXCOM INC. BUSINESS SNAPSHOT
  • TABLE 29: ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
  • TABLE 30: ANIMAS CORPORATION BUSINESS SNAPSHOT
  • TABLE 31: ECHO THERAPEUTICS COMPANY SNAPSHOT
  • TABLE 32: INSULET CORPORATION BUSINESS SNAPSHOT
  • TABLE 33: GLYSENS INC. BUSINESS SNAPSHOT
  • TABLE 34: SENSEONICS, INC. SNAPSHOT

List of Figures

  • FIG. 1: PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
  • FIG. 2: GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
  • FIG. 3: PREDISPOSITION AND RISK FACTORS SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
  • FIG. 4: GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20 79 YEARS)
  • FIG. 5: GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
  • FIG. 6: OCCURENCE OF HYPERGLYCEMIA IN ICUS
  • FIG. 7: TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
  • FIG. 8 : OP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
  • FIG. 9 : OP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
  • FIG. 10: TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
  • FIG. 11: TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010 2014 (SEPTEMBER)
  • FIG. 13: MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
  • FIG. 14: GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
  • FIG. 15: PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)
  • FIG. 16: GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
  • FIG. 17: CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
  • FIG. 18: CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
  • FIG. 19: MEDTRONIC REVENUE BY GEOGRAPHY (2014)
  • FIG. 20: SWOT ANALYSIS OF MEDTRONIC PLC
  • FIG. 21: SWOT ANALYSIS OF DEXCOM INC.
  • FIG. 22: REVENUE BY BUSINESS SEGMENT (2014)
  • FIG. 23: SWOT ANALYSIS OF ABBOTT DIABETIC CARE
  • FIG. 24: SWOT ANALYSIS OF ANIMAS CORPORATION
  • FIG. 25: SWOT ANALYSIS OF ECHO THERAPEUTICS
  • FIG. 26: SWOT ANALYSIS OF INSULET CORPORATION
  • FIG. 27: SWOT ANALASIS OF GLYSEN INCORPORATED
  • FIG. 28: SWOT ANALYSIS OF SENSEONICS, INC.
Back to Top